Acipimox

CLINICAL USE

Hyperlipidaemia

DOSE IN NORMAL RENAL FUNCTION

250 mg 2 or 3 times daily

PHARMACOKINETICS

Molecular weight : 154.1

%Protein binding : 0

%Excreted unchanged in urine : 86–90

Volume of distribution (L/kg) : 0.3–0.4

half-life – normal/ESRD (hrs) : 2/Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

40–80 250 mg daily 20–40 250 mg alternate days. <20 See ‘Other Information’

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD : Likely dialysability. Dose as in GFR<20 mL/min

HD : Dialysed. Dose as in GFR<20 mL/min

HDF/high flux : Dialysed. Dose as in GFR<20 mL/min

CAV/VVHD : Dialysed. Dose as in GFR=20–40 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

Take with or after meals

OTHER INFORMATION

Females are twice as likely as males to suffer from side effects, e.g. flushing, pruritus and skin rashes

Doses up to 1200 mg have been given safely for long periods After a 5 hour dialysis 70% of the drug had been removed

Dollery advises the doses given in the table, down to 20 mL/minute, but nothing after that. Micromedex gives the following recommendations: GFR: 30–60 mL/min 150 mg twice daily GFR: 10–30 mL/min 150 mg once daily GFR:

<10 : mL/min 150 mg alternate days

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home